Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations

被引：43

作者：

Burns, Timothy F. ^{[1
]}

Borghaei, Hossein ^{[2
]}

Ramalingam, Suresh S. ^{[3
]}

Mok, Tony S. ^{[4
]}

Peters, Solange ^{[5
]}

机构：

[1] Univ Pittsburgh Med Ctr UPMC, Hillman Canc Ctr, Pittsburgh, PA USA

[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[3] Emory Univ, Sch Med, Winship Canc Inst, Div Med Oncol, Atlanta, GA USA

[4] Chinese Univ Hong Kong, Dept Clin Oncol, State Lab Translat Oncol, Hong Kong, Peoples R China

[5] Lausanne Univ, Dept Oncol, Ctr Hosp Univ Vaudois, Lausanne, Switzerland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 35期

关键词：

SELUMETINIB PLUS DOCETAXEL; PROGRESSION-FREE SURVIVAL; K-RAS MUTATIONS; SELECTIVE-INHIBITION; PREDICTIVE-VALUE; CHINESE PATIENTS; POOLED ANALYSIS; MEK INHIBITORS; NEVER SMOKERS; WILD-TYPE;

D O I：

10.1200/JCO.20.00744

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：4208 / 4218

页数：14

共 117 条

[1] KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition [J].

Adderley, Helen ;

Blackhall, Fiona H. ;

Lindsay, Colin R. .

EBIOMEDICINE, 2019, 41 :711-716

[2]

[Anonymous], CANC FACTS FIG 2019

[3]

[Anonymous], 2013, J THORAC DIS S2, V5, pS168

[4] Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes [J].

Aredo, Jacqueline, V ;

Padda, Sukhmani K. ;

Kunder, Christian A. ;

Han, Summer S. ;

Neal, Joel W. ;

Shrager, Joseph B. ;

Wakelee, Heather A. .

LUNG CANCER, 2019, 133 :144-150

[5] A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling [J].

Athuluri-Divakar, Sai Krishna ;

Vasquez-Del Carpio, Rodrigo ;

Dutta, Kaushik ;

Baker, Stacey J. ;

Cosenza, Stephen C. ;

Basu, Indranil ;

Gupta, Yogesh K. ;

Reddy, M. V. Ramana ;

Ueno, Lynn ;

Hart, Jonathan R. ;

Vogt, Peter K. ;

Mulholland, David ;

Guha, Chandan ;

Aggarwal, Aneel K. ;

Reddy, E. Premkumar .

CELL, 2016, 165 (03) :643-655

[6] The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma [J].

Biernacka, Anna ;

Tsongalis, Peter D. ;

Peterson, Jason D. ;

de Abreu, Francine B. ;

Black, Candice C. ;

Gutmann, Edward J. ;

Liu, Xiaoying ;

Tafe, Laura J. ;

Amos, Christopher I. ;

Tsongalis, Gregory J. .

CANCER GENETICS, 2016, 209 (05) :195-198

[7] A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) [J].

Blumenschein, G. R., Jr. ;

Smit, E. F. ;

Planchard, D. ;

Kim, D. -W. ;

Cadranel, J. ;

De Pas, T. ;

Dunphy, F. ;

Udud, K. ;

Ahn, M. -J. ;

Hanna, N. H. ;

Kim, J. -H. ;

Mazieres, J. ;

Kim, S. -W. ;

Baas, P. ;

Rappold, E. ;

Redhu, S. ;

Puski, A. ;

Wu, F. S. ;

Jaenne, P. A. .

ANNALS OF ONCOLOGY, 2015, 26 (05) :894-901

[8] Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment [J].

Bordi, Paola ;

Tiseo, Marcello ;

Rofi, Eleonora ;

Petrini, Iacopo ;

Restante, Giuliana ;

Danesi, Romano ;

Del Re, Marzia .

CLINICAL LUNG CANCER, 2017, 18 (06) :692-697

[9]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[10] Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer [J].

Broutin, Sophie ;

Stewart, Adam ;

Thavasu, Parames ;

Paci, Angelo ;

Bidart, Jean-Michel ;

Banerji, Udai .

BRITISH JOURNAL OF CANCER, 2016, 115 (05) :549-552

← 1 2 3 4 5 6 7 8 9 10 →